Vabysmo Side Effects

Generic name: faricimab ophthalmic

Medically reviewed by Drugs.com. Last updated on Aug 24, 2024.

Note: This document provides detailed information about Vabysmo Side Effects associated with faricimab ophthalmic. Some dosage forms listed on this page may not apply specifically to the brand name Vabysmo.

Applies to faricimab ophthalmic: intraocular solution.

Serious side effects of Vabysmo

Along with its needed effects, faricimab ophthalmic (the active ingredient contained in Vabysmo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor or nurse immediately if any of the following side effects occur while taking faricimab ophthalmic:

More common side effects

• bloody eye
• redness of the eye

Less common side effects

• blurred vision
• change in vision
• eye pain
• loss of vision
• red, sore eyes
• seeing floaters, veil or curtain appearing across part of vision
• seeing floating dark spots or material before the eyes
• tearing

Rare side effects

• eye irritation
• seeing light flashes
• watering of the eyes

Incidence not known

• chest pain, discomfort, or tightness
• fast heartbeat
• fever
• hives, itching, rash
• hoarseness
• irritation
• joint pain, stiffness, or swelling
• nausea
• pain or discomfort in the arms, jaw, back, or neck
• redness of the skin
• stroke
• sweating
• swelling of the eyelids, face, lips, hands, or feet
• trouble breathing
• vomiting

For healthcare professionals

Applies to faricimab ophthalmic: intravitreal solution.

Cardiovascular adverse events

• Common (1% to 10%): Arterial thromboembolic events (defined as nonfatal stroke, nonfatal myocardial infarction, vascular death [including deaths of unknown cause])^[Ref]

In the neovascular age-related macular degeneration studies, arterial thromboembolic events were reported in 1% of patients during the first year. In the diabetic macular edema studies, arterial thromboembolic events were reported in 2% of patients during the first year.^[Ref]

Hypersensitivity

• Frequency not reported: Hypersensitivity reactions^[Ref]

Immunologic

• Very common (10% or more): Anti-drug antibodies (up to 10.4%)^[Ref]

Ocular

• Very common (10% or more): Cataract (10.7%)
• Common (1% to 10%): Conjunctival hemorrhage, eye pain, increased intraocular pressure, increased lacrimation, retinal pigment epithelial tear, vitreous floaters
• Uncommon (0.1% to 1%): Blurred vision, corneal abrasion, conjunctival hyperemia, endophthalmitis, eye irritation, eye pruritus, iridocyclitis, iritis, ocular discomfort, ocular hyperemia, retinal tear, sensation of foreign body, uveitis, reduced visual acuity, vitreous hemorrhage, vitritis
• Rare (0.01% to 0.1%): Rhegmatogenous retinal detachment, transiently reduced visual acuity^[Ref]

Frequently asked questions

• What is the difference between Vabysmo and Eylea?
• What is the mechanism of action for Vabysmo?

Further information

Vabysmo side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.

Medical Disclaimer